OncoCyte Corporation

OCX

US68235C2061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
2.95 ^USD	+1.03%		+4.24%	+18.00%

06-28	Transcript : OncoCyte Corporation - Shareholder/Analyst Call
06-18	OncoCyte Names Andrea James Chief Financial Officer	MT

OncoCyte Corporation Enters into A Separation Agreement with Vice President-Marketing, Kristine Mechem

January 28, 2019 at 05:05 pm

On January 22, 2019, OncoCyte Corporation entered into a Separation Agreement with Vice President-Marketing, Kristine Mechem in connection with the termination of her employment.

Latest news about OncoCyte Corporation

Transcript : OncoCyte Corporation - Shareholder/Analyst Call	06-28
OncoCyte Names Andrea James Chief Financial Officer	06-18	MT
OncoCyte Corporation Appoints Andrea James as Chief Financial Officer	06-17	CI
Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial	06-03	CI
Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results	05-30	CI
Transcript : OncoCyte Corporation, Q1 2024 Earnings Call, May 15, 2024	05-15
Earnings Flash (OCX) ONCOCYTE CORPORATION Reports Q1 Revenue $176,000, vs. Street Est of $0.4M	05-15	MT
OncoCyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
OncoCyte Corporation announced that it has received $15.807655 million in funding	04-24	CI
Broadwood Capital, Inc. Engages with OncoCyte Corporation	04-15	CI
Sector Update: Health Care Stocks Steady Pre-Bell Friday	04-12	MT
Transcript : OncoCyte Corporation, Q4 2023 Earnings Call, Apr 12, 2024	04-12
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	04-12	CI
OncoCyte Agrees to $15.8 Million Private Placement of Stock, Warrants	04-12	MT
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	04-11	CI
OncoCyte Corporation announced that it expects to receive $15.807655 million in funding	04-10	CI
Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays	12-06	CI
Needham Adjusts Price Target on OncoCyte to $3.60 From $4.25, Maintains Buy Rating	11-09	MT
Transcript : OncoCyte Corporation, Q3 2023 Earnings Call, Nov 09, 2023	11-09
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
OncoCyte Corporation(NasdaqCM:OCX) dropped from S&P Global BMI Index	23-09-18	CI
Sector Update: Health Care Stocks Steady Late Afternoon	23-08-28	MT
Sector Update: Health Care Stocks Rising in Afternoon Trading	23-08-28	MT
OncoCyte Says VitaGraft Kidney Diagnostic Test to Receive Medicare, Medicaid Coverage	23-08-28	MT
Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage	23-08-28	CI

Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Companyâs products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for OncoCyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.95 USD

Average target price

4.417 USD

Spread / Average Target

+49.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
ONCOCYTE CORPORATION	+18.00%	39.43M
EXACT SCIENCES CORPORATION	-42.89%	7.8B
GUARDANT HEALTH, INC.	+6.77%	3.53B
BGI GENOMICS CO., LTD.	-27.06%	1.84B
VERACYTE, INC.	-21.23%	1.66B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+9.31%	951M
CAREDX, INC	+29.42%	811M
SEEGENE, INC.	-12.66%	670M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-26.12%	533M
CURIOX BIOSYSTEMS CO., LTD	+1.19%	297M

Bio Diagnostics & Testing